UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA
Clinical trials for UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA explained in plain language.
Never miss a new study
Get alerted when new UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA trials appear
Sign up with your email to follow new studies for UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New malaria combo shows promise in kids – could fight drug resistance
Disease control CompletedThis study tested a new two-drug combination (KAF156 plus a special form of lumefantrine) in 295 children aged 6 months to 18 years with uncomplicated malaria. The goal was to see if the treatment safely clears the parasite and prevents the infection from coming back. The approac…
Matched conditions: UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New malaria combo shows promise in clearing parasite
Disease control CompletedThis study tested a combination of two anti-malarial drugs, cipargamin and KLU156, in 60 people with uncomplicated Plasmodium falciparum malaria. Participants were at least 12 years old and had a confirmed infection. The main goal was to see if the drugs could clear the malaria p…
Matched conditions: UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New malaria pill shows promise in large trial
Disease control CompletedThis study tested a new malaria drug called KLU156 in over 1,700 adults and children with uncomplicated malaria. It compared KLU156 to a standard treatment, Coartem, to see if it works as well. Some participants continued taking KLU156 for up to two years to check its safety with…
Matched conditions: UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New malaria pill shows promise in early trial
Disease control CompletedThis Phase 2 trial tested an experimental drug called INE963 in 52 adults with uncomplicated Plasmodium falciparum malaria. The main goal was to see how quickly the drug clears malaria parasites from the blood. Researchers also checked the 28-day cure rate. The study is part of a…
Matched conditions: UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC